Microbiological and epidemiological studies of Enterococcus faecium resistant to amoxycillin in a university hospital in eastern France

Clinical Microbiology and Infection

Volumn 10, Issue 5, 2004, Pages 441-447

  Thouverez, M ^a   Talon, Daniel ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Enterococcus faecium; Molecular epidemiology; Resistance to amoxycillin; Risk factors

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; KANAMYCIN; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROCOCCUS FAECIUM; EPIDEMIC; EPIDEMIOLOGICAL DATA; FEMALE; FRANCE; HEMATOLOGY; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; STRAIN DIFFERENCE; UNIVERSITY HOSPITAL; WARD;

ENTEROCOCCUS; ENTEROCOCCUS FAECIUM;

EID: 2642576919     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.00849.x     Document Type: Article

References (32)

1. Emori TG, Gaynes RP. An overview of nosocomial infections, including role of the microbiology laboratory. Clin Microbiol Rev 1993; 6: 428-442.
2. Handwerger S, Perlman DC, Altarac D, McAuliffe V. Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci. Clin Infect Dis 1992; 14: 655-661.
3. Huicke MM, Sahm DF, Gilmore MS. Multiple-drug resistant enterococci. the nature of the problem and an agenda for the future. Emerg Infect Dis 1998; 4: 239-249.
4. Wade JJ. The emergence of Enterococcus faecium resistant to glycopeptides and other agents - a preliminary report. J Hosp Infect 1995; 30: 483-493.
5. Handwerger S, Raucher B, Altarac D et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin and gentamicin. Clin Infect Dis 1993; 16: 750-755.
6. Chow JW, Kuritza A, Schaels DM, Green M, Sahm DF, Zervos MJ. Clonal spread of vancomycin-resistant Enterococcus faecium between patients in three hospitals in two states. J Clin Microbiol 1993; 32: 344-346.
7. Montecalvo MA, Horowitz H, Gedris C et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994; 38: 1363-1367.
8. Bertrand X, Thouverez M, Bailly P, Cornette C, Talon D and members of Réseau Franc-Comtois de Lutte contre les Infections Nosocomiales. Clinical and molecular epidemiology of hospital Enterococcus faecium isolates in eastern France. J Hosp Infect 2000; 45: 125-134.
9. Observatoire National de l'Epidemiologie de la Resistance Bacterienne aux Antibiotiques (ONERBA). Entérocoques ré sistants aux glycopeptides: portage et infection. Rapport technique de synthèse pour l'année 1997, résultats 1998, 35-40.
10. Moulin F, Dumontier S, Saulnier P et al. Surveillance of intestinal colonization and of infection by vancomycin-resistant enterococci in hospitalized cancer patients. Clin Microbiol Infect 1996; 2: 192-201.
11. Marcus N, Peled N, Yagupsky P. Rapid increase in the prevalence of antimicrobial drug resistance among enterococcal blood isolates in southern Israel. Eur J Clin Microbiol Infect Dis 1997; 16: 913-915.
12. Carias LL, Rudin SD, Donskey CJ, Rice LB. Genetic linkage and co-transfer of a novel transposon (Tn 5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin isolate. J Bacteriol 1998; 180: 4426-4434.
13. Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1996; 17: 576-578.
14. Bonten MJ, Willems R, Weinstein RA. Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 2001; 1: 314-325.
15. Soussy CJ, Carret G, Cavallo JD et al. Antibiogram Committee of the French Microbiology Society. Report 2000-01. Pathol Biol 2000; 48: 832-871.
16. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. Villanova, PA: NCCLS, 1993.
17. Elaichouni A, Verschraegen G, Claeys G, Devleeschouwer M, Godard C, Vaneechoutte M. Pseudomonas aeruginosa serotype O12 outbreak studied by arbitrary primer PCR. J Clin Microbiol 1995; 32: 666-671.
18. Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification at the species level of clinically relevant enterococci by PCR. J Clin Microbiol 1995; 33: 24-27.
19. Murray BE, Singh KV, Heath JD, Sharma BR, Weinstock GM. Comparison of genomic DNA of different enterococcal isolates using restriction endonucleases with infrequent recognition sites. J Clin Microbiol 1990; 28: 2059-2063.
20. Murray BE, Singh KV, Markowitz SM et al. Evidence for clonal spread of a single strain of β-lactamase-producing Enterococcus faecalis to six hospitals in five states. J Infect Dis 1991; 163: 780-785.
21. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233-2239.
22. Rybkine T, Mainardi JL, Sougakoff W, Collatz E, Gutmann L. Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of β-lactam resistance. J Infect Dis 1998; 178: 159-163.
23. El Amin N, Wretlind B, Wenger A, Brandt V, Bille J. Ampicillin-sensitive, imipenem-resistant strrains of Enterococcus faecium. J Clin Microbiol 2002; 40: 378.
24. Brandt V, Wenger A, Bille J. Enterococcal bacteremia 10 years apart: What has changed and what has not! Clin Microbiol Infect 2000; 6 (suppl 1): 63.
25. Fortún J, Coque TM, Martín-Dávila P et al. Risk factors associated with ampicillin resistance in patients with bacteraemia caused by Enterococcus faecium. J Antimicrob Chemother 2002; 50: 1003-1009.
26. Chirurgi VA, Oster SE, Goldberg AA, McCabe RE. Nosocomial acquisition of beta-lactamase-negative, ampicillin-resistant Enterococcus. Arch Intern Med 1992; 152: 1457-1461.
27. McCarthy AE, Victor G, Ramotar K, Toye B. Risk factors for acquiring amipicillin-resistant enterococci and clinical outcomes at a Canadian tertiary-care hospital. J Clin Microbiol 1994; 32: 2671-2676.
28. Moellering RC. Enterococcal infections in patients treated with moxalactam. Rev Infect Dis 1982; 4 (suppl): S708-S711.
29. Yu V. Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic. Ann Intern Med 1981; 94: 784-785.
30. Pallares R, Pujol M, Pena C, Ariza J, Martin R, Gudiol F. Cephalosporins as a risk factor for nosocomial Enterococcus faecalis bacteremia. A matched case-control study. Arch Intern Med 1993; 153: 1581-1586.
31. Noskin GA, Peterson LR, Warren JR. Enterococcus faecium and Enterococcus faecalis bacteraemia: acquisition and outcome. Clin Infect Dis 1995; 20: 296-301.
32. Floret N, Thouverez M, Thalamy B, Estavoyer JM, Talon D. Evaluation of vancomycin use in a large University-affiliated hospital in eastern France in 1999. Pharm World Sci 2001; 23: 93-97.